title: Cutting the cost of South African antiretroviral therapy using newer, safer drugs.
abstract: Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.
authors.affiliation: Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa. fventer@wrhi.ac.za.
authors.forename: W F
authors.initials: WF
authors.lastname: Venter
authors.forename: B
authors.initials: B
authors.lastname: Kaiser
authors.forename: Y
authors.initials: Y
authors.lastname: Pillay
authors.forename: F
authors.initials: F
authors.lastname: Conradie
authors.forename: G B
authors.initials: GB
authors.lastname: Gomez
authors.forename: P
authors.initials: P
authors.lastname: Clayden
authors.forename: M
authors.initials: M
authors.lastname: Matsolo
authors.forename: C
authors.initials: C
authors.lastname: Amole
authors.forename: L
authors.initials: L
authors.lastname: Rutter
authors.forename: F
authors.initials: F
authors.lastname: Abdullah
authors.forename: E J
authors.initials: EJ
authors.lastname: Abrams
authors.forename: C P
authors.initials: CP
authors.lastname: Casas
authors.forename: M
authors.initials: M
authors.lastname: Barnhart
authors.forename: A
authors.initials: A
authors.lastname: Pillay
authors.forename: A
authors.initials: A
authors.lastname: Pozniak
authors.forename: A
authors.initials: A
authors.lastname: Hill
authors.forename: L
authors.initials: L
authors.lastname: Fairlie
authors.forename: M
authors.initials: M
authors.lastname: Boffito
authors.forename: M
authors.initials: M
authors.lastname: Moorhouse
authors.forename: M
authors.initials: M
authors.lastname: Chersich
authors.forename: C
authors.initials: C
authors.lastname: Serenata
authors.forename: J
authors.initials: J
authors.lastname: Quevedo
authors.forename: G
authors.initials: G
authors.lastname: Loots
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics* / Q000379:methods; D002986:Clinical Trials as Topic; D017046:Cost Savings; D016527:Drug Costs; D055808:Drug Discovery; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D013019:South Africa
chemical_list: D019380:Anti-HIV Agents